렘데시비르만 고집하는 트럼프 대통령

렘데시비르는 길리어드사이언스 회사가 만든 에볼라 치료제로 개발해온 항바이러스제입니다.

 

그런데 최근 미국에서 진행한 초기 임상시험에서 코로나바이러스 치료에 효과가 나타났다는 발표가 나오면서 세계적인 주목을 받고 있습니다.

 

다음은 미국 식품의약국(FDA)은 이날 렘데시비르에 대한 긴급사용을 승인한 내용의 기사입니다.

 

The US's Food and Drug Administration (FDA) has authorised emergency use of the Ebola drug remdesivir for treating the coronavirus.

The authorisation means the anti-viral drug can now be used on people who are hospitalised with severe Covid-19.

미국 식품의약국(FDA)은 코로나바이러스 치료를 위해 에볼라 약품인 렘데시비르를 긴급 사용하는 것을 허가했다.
허가란 항바이러스제가 현재 심각한 Covid-19로 병원에 입원한 사람들에게 사용될 수 있다는 것을 의미한다.

 

A recent clinical trial showed the drug helped shorten the recovery time for people who were seriously ill.

However, it did not significantly improve survival rates.

최근의 임상 실험은 그 약이 중증 환자의 회복 시간을 단축하는데 도움을 주었다는 것을 보여주었다.
하지만 생존율을 크게 개선하지는 못했다.

 

Experts have warned the drug - which was originally developed to treat Ebola, and is produced by Gilead pharmaceutical company in California - should not be seen as a "magic bullet" for coronavirus.

전문가들은 에볼라를 치료하기 위해 개발되었으며 캘리포니아의 길리어드 제약회사가 생산한 이 약이 코로나바이러스의 "마법 총알"로 간주되어서는 안 된다고 경고했다.

 

The drug interferes with the virus's genome, disrupting its ability to replicate.

그 약은 바이러스의 게놈을 방해하여 복제 능력을 교란시킨다.

 

During a meeting with US President Donald Trump in the Oval Office, Gilead Chief Executive Daniel O'Day said the FDA authorisation was an important first step. 

도널드 트럼프 미국 대통령과 백악관 집무실에서 만난 다니엘 오데이 길리어드 최고경영자(CEO)는 FDA 허가가 중요한 첫 단계라고 말했다.

 

The company would donate 1.5 million vials of the drug, he said.

이 회사는 150만 병의 약품을 기증할 것이라고 그는 말했다.

 

FDA Commissioner Stephen Hahn also said at the meeting: "It's the first authorised therapy for Covid-19, so we're really proud to be part of it."

Emergency FDA authorisation is not the same as formal approval, which requires a higher level of review.

스티븐 한 미 식품의약국(FDA) 국장 역시 이 회의에서 "코비드-19를 위한 최초의 공인된 치료법이기 때문에 우리는 이 치료법의 일부가 된 것이 정말 자랑스럽다"고 말했다.
긴급 FDA 허가는 정식 승인과 같지 않아 더 높은 수준의 검토가 필요하다.

 

 

The drug did not cure Ebola, and Gilead says on its website: "Remdesivir is an experimental medicine that does not have established safety or efficacy for the treatment of any condition." Gilead also warns of possible serious side-effects.

길리어드는 웹 싸이트에 이 약은 에볼라를 치료하지 않았으며 "렘디비르는 어떤 질환의 치료에도 안전이나 효능이 확립되지 않은 실험적인 약"이라고 밝히고 있다. 길리어드는 또한 심각한 부작용을 경고한다.

 

However, President Trump has been a vocal supporter of remdesivir as a potential treatment for the coronavirus.

In its clinical trial, whose full results are yet to be released, the US National Institute of Allergy and Infectious Diseases (NIAID) found that remdesivir cut the duration of symptoms from 15 days down to 11. 

다만 트럼프 대통령은 코로나바이러스의 잠재적 치료제로서 렘디비르의 목소리를 높여왔다.
아직 완전한 결과가 나오지 않은 미국 국립알레르기감염병연구소(NIAID)의 임상시험에서 렘데시비르가 15일에서 11일로 증상 지속 기간을 단축한 것으로 나타났다.

 

The trials involved 1,063 people at hospitals around the world - including the US, France, Italy, the UK, China and South Korea. Some patients were given the drug and others were given a placebo (dummy) treatment.

Dr Anthony Fauci who runs NIAID, said that remdesivir had "a clear-cut, significant, positive effect in diminishing the time to recovery".

이 실험에는 미국, 프랑스, 이탈리아, 영국, 중국, 한국을 포함한 전 세계 병원에서 1,063명이 참여했다. 어떤 환자들은 약을 먹었고 다른 환자들은 위약 치료를 받았다.
NIAID를 운영하는 Anthony Fauci 박사는 렘디비르가 "회복의 시간을 단축시키는 데 분명하고, 의미심장하며, 긍정적인 효과가 있다"고 말했다.

 

However, although remdesivir may aid recovery - and possibly stop people having to be treated in intensive care - the trials did not give any clear indication whether it can prevent deaths from coronavirus.

As much remains uncertain about the treatment regime, Gilead suggests a 10-day dosing duration for patients on ventilators and five days for patients who are not. 

그러나, 비록 렘디비르가 회복에 도움을 줄 수 있고, 중환자실에서 치료를 받아야 하는 사람들을 막을 수도 있지만, 그 실험은 그것이 코로나바이러스로 인한 죽음을 막을 수 있을지에 대한 명확한 징후를 보여주지는 못했다.
길리어드는 치료 체계가 불확실한 만큼 환풍기 환자들은 10일, 환풍기 환자들은 5일 동안 복용할 것을 제안한다.

 

 

* 기사 내용 및 사진 출처: bbc